Identification of a novel germline  SPOP  mutation in a family with hereditary prostate cancer by Zuhlke, Kimberly A. et al.
Identif|cationof aNovelGermline SPOPMutation
in a FamilyWithHereditary ProstateCancer
Kimberly A. Zuhlke,1* Anna M. Johnson,1 Scott A. Tomlins,2 Nallasivam Palanisamy,2
John D. Carpten,3 Ethan M. Lange,4 William B. Isaacs,5 and Kathleen A. Cooney1
1Departmentof InternalMedicine,UniversityofMichiganMedical School, AnnArbor,Michigan
2MichiganCenter forTranslational Pathology,UniversityofMichiganMedical School, AnnArbor,Michigan
3TranslationalGenomics Research Institute, Phoenix, Arizona
4DepartmentofGenetics,UniversityofNorthCarolina SchoolofMedicine,ChapelHill,NorthCarolina
5DepartmentofUrology,The JohnsHopkinsUniversity SchoolofMedicine,Baltimore,Maryland
BACKGROUND. Family history of prostate cancer is a well-recognized risk factor. Previous
linkage studies have reported a putative prostate cancer susceptibility locus at chromosome
17q21–22. SPOP (Speckle-type POZ protein) maps to the 17q21–22 candidate linkage region
and is one of the most frequently mutated genes in sporadic prostate cancers.
METHODS. We performed targeted next generation sequencing to analyze 2009 exons from
202 genes in a candidate linkage region on chromosome 17q21–22 using 94 unrelated familial
prostate cancer cases from the University of Michigan Prostate Cancer Genetics Project (n¼ 54)
and Johns Hopkins University (n¼ 40) including the exons and UTRs of SPOP.
RESULTS. We identified a novel SPOP missense mutation (N296I) in a man with prostate
cancer diagnosed at age 43. This mutation completely segregates with prostate cancer affection
status among the men in this family. The N296I mutation resides within the evolutionarily
conserved Bric-a-brac, Tramtrack, Broad-complex (BTB) domain, involved in recruiting targets
to Cul3 for degradation. Analysis of the prostate tumor from this individual verified the
presence of heterozygous N296I as well as an ERG fusion.
CONCLUSIONS. We have discovered a novel mutation in SPOP that tracks with
prostate cancer within a family and is predicted to be deleterious. Taken together, our results
implicate SPOP as a candidate gene for hereditary prostate cancer. Prostate 74:983–990, 2014.
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INTRODUCTION
Prostate cancer is the most common non-cutaneous
cancer diagnosed among American men and the
second leading cause of cancer death with an estimated
233,000 new cases and 29,480 deaths expected in the
United States in 2014. Known risk factors for prostate
cancer are increasing age, African American race, and
positive family history of the disease. Studies per-
formed with the objective of elucidating a heritable
component have succeeded in identifying a region of
genetic susceptibility on chromosome 17q first reported
by Lange et al. [1] on the basis of linkage analysis of
175 pedigrees of families with hereditary prostate
cancer (HPC) from the University of Michigan Prostate
Cancer Genetics Project (UM-PCGP). Fine mapping of
chromosome 17q, using 453 pedigrees from the UM-
PCGP and Johns Hopkins University (JHU) refined this
region of interest to chromosome 17q21–22 [2]. Further
analysis of a subset of 147 families with four or more
affected men and an average age of prostate cancer
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diagnosis 65 years narrowed the candidate interval
(1-LOD support interval) for a putative susceptibility
gene to a 10 cM region of 17q that contains over 75
known genes. We have previously reported the identi-
fication of a rare but recurrent G84E (rs138213197)
missense mutation in HOXB13 from the chromosome
17q-linked families described herein [3]. Carriers of
G84E were reported to have a 10- to 20-fold increased
risk of developing prostate cancer with the highest
frequency in men with early-onset and familial prostate
cancer. Subsequent studies have confirmed this report
providing further evidence that rare genetic variants
play a role in prostate cancer susceptibility [4–13].
Genome wide association studies of prostate cancer in
populations of men of African and European descent
have also identified risk variants within 17q21. Specifi-
cally, rs7210100 [14] and rs1165049 [15] located in
intron 1 and downstream of ZNF652 respectively.
ZNF652 is located within a gene-dense region of 17q21
that harbors prostate cancer susceptibility genes
HOXB13, PRAC, and SPOP. To date, chromosome
17q21–22 remains one of the most reproducible linkage
regions for prostate cancer susceptibility loci.
The Speckle-type POZ protein or SPOP gene, which
maps to the 17q21–22 candidate linkage region, is one
of the most frequent somatically mutated genes in
prostate cancer. Initially described by Kan et al. [16],
SPOP mutations have been observed in (2/58) [16]
and 14/111 [17] prostate cancers and (2/7) tumors
from men with high risk disease [18]. SPOP encodes
the substrate-binding subunit of a Cullin-based E3
ubiquitin ligase. Studies using the MCF-7 breast cancer
cell line have shown SPOP directly impacts cancer cell
growth and invasion, suggesting that SPOP may
function as a tumor suppressor gene (TSG) in breast
and possibly other cancers [19]. Tissue microarray
screening for SPOP expression in 18 cancer types from
different organs revealed high expression of SPOP in
kidney, endometrial, and germ cell cancers when
compared to normal tissues [20]. Additionally, recent
evidence has shown that the previously reported
prostate-cancer-associated mutants of SPOP cannot
promote androgen receptor (AR) ubiquitination [21],
suggesting that SPOP is part of the degradation system
for AR, an important driver of prostate carcinogenesis.
In the present study, we set out to analyze SPOP
germline sequence data from 94 familial prostate cancer
cases with evidence of linkage to chromosome 17
compiled at the University of Michigan and the JHU.
METHODS
Patient Selection
University of Michigan Prostate Cancer Genetics
Project (UM-PCGP). UM-PCGP prostate cancer cases
were restricted to (1) men diagnosed with prostate
cancer with at least one living first- or second-degree
relative also diagnosed with prostate cancer or (2) men
diagnosed with prostate cancer at <56 years of age.
We confirmed the diagnosis of prostate cancer by
medical record review whenever possible. All subjects
provided written informed consent to participate in
the study. The protocol and consent documents were
approved by the University of Michigan Medical
School Institutional Review Board Health Insurance
Portability and Accountability Act (HIPAA) regula-
tions and all subjects gave written informed consent.
Johns Hopkins University. HPC families each had at
least three first-degree relatives affected with prostate
cancer. We verified diagnosis of prostate cancer by
medical records. The protocol and consent documents
were approved by the Johns Hopkins School of
Medicine Institutional Review Board and all subjects
gave written informed consent.
Discordant Sibling Pairs
The details of the discordant sibling pair (DSP)
project have been described elsewhere [22]. For the
present study, 569 families were identified in which
DNA was available from at least one pair of brothers
discordant for prostate cancer.
Targeted Sequencingof SPOP
We selected the youngest prostate cancer case with
available DNA from 94 prostate cancer families (40
families from JHU and 54 from the UM-PCGP) as
described previously [3]. Seven of the families were of
African descent, 2 were of Asian descent, and the
remaining 85 described themselves as being of Europe-
an descent. A primer library was designed for amplifi-
cation of 7,053 base pairs (bp) of SPOP including all
exons, intron/exon boundaries, and the 50 and 30
untranslated regions. We then used the RainDance
RDT 1000 system (RainDance Technologies, Inc., Lex-
ington, MA) to amplify 3mg of sheared genomic DNA
from each sample using our primer library. Purified
amplicons were used as template for sequencing using
the Life Technologies SOLiDTM system version 4.0
fragment library methodology (Life Technologies Cor-
poration, Carlsbad, CA). Sequence data processing
was performed using Bioscope to align the sequences
to the genomic reference (Build 36, hg18). Variant
detection was performed using SamTools 1.3 [23] and
SolSNP 1.1. We confirmed and tested all variant
sequences in family members using standard Sanger
sequencing, capillary electrophoresis technology and
BigDye1 Terminator chemistry (Life Technologies).
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Tumor Sequencing
Prostate tumor DNA from the index case was
extracted using the QIAamp DNA FFPE tissue kit
(Qiagen, Valencia, CA). Sanger sequencing of N296I
was performed using custom SPOP primers as de-
scribed above.
Immunohistochemistry
Hematoxylin and Eosin (H&E) slides from the
prostatectomy of the index case were reviewed and
re-graded according to current ISUP guidelines.
ERG immunostaining was performed essentially as
described [24,25] using pre-diluted ERG antibody
(provided by Ventana Medical Systems, Tuscon, AZ)
using the automated Discovery XT staining platform
(Ventana Medical Systems).
GenotypingAssays
We genotyped N296I in the DSP cohort using a
custom TaqMan SNP assay (Life Technologies). Allelic
discrimination was performed on an ABI Prism
7900HT Sequence Detection System and SDS version
2.1 software (Applied Biosystems, Foster City, CA).
Genotyping call rate was 99%.
RESULTS
Molecular Study Resultof the IndexCase
Targeted next-generation sequencing revealed a
novel heterozygous 1,358 A>T mutation (Fig. 1) in an
individual of European descent diagnosed with Glea-
son 3þ 4¼ 7 prostate cancer at age 43 (NM_001007226).
The missense mutation is a single A to T transversion in
exon 11 resulting in an amino acid substitution of
asparagine to isoleucine at codon 296 (N296I). This
variant was confirmed by Sanger sequencing. No
additional SPOP missense variants were observed in
the remaining 93 HPC probands.
Molecular Study ResultofOther FamilyMembers
Sanger sequencing of additional family members
revealed complete segregation of N296I and prostate
cancer affection status amongst the men in this family
(Fig. 2). Sequence data from five additional male
relatives revealed that the father and a brother with
prostate cancer carry the mutation, as does another
brother affected with both prostate and kidney cancer.
Two unaffected brothers, ages 46 and 56, do not carry
the N296I allele. Female relatives with DNAwere also
genotyped, the mother of the proband did not carry
the N296I, yet the sister of the proband was positive
for the variant. To our knowledge, neither of the
female relatives has been diagnosed with cancer.
Molecular andHistopathologic Characterization
of the ProstateTumor
Sanger sequencing of DNA extracted from archival
tissue confirmed the presence of the heterozygous
N296I variant in the prostate tumor from the proband.
Additionally, ERG expression was observed in a
Fig. 1. Location of the SPOPN296Imutation.A:The 374 amino acid SPOPprotein consists of anN-terminalmeprin and TRAF-homology
(MATH)domain,aBTBsubstratebinding,otherwiseknownasapoxvirusandzinc finger (POZ),domain,andaC-terminalnuclearlocalization
sequence.TheSPOPN296Imutationresidesin theBric-a-brac,Tramtrack,Broad-complex(BTB)bindingdomain.Thesomaticmutationsiden-
tified in prostate tumors are located in the MATH domain.B: Chromatograms showing the presence of the N296I missense mutation in
bothgermlineandtumorDNAfromour indexcase.
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Gleason 3þ 4¼ 7 focus of prostate cancer from the
index case consistent with the presence of an ERG
rearrangement [26] (Fig. 3). SPOP expression was also
observed in the prostate tissue (data not shown).
Molecular Study Resultof DSPs
No additional N296I carriers were detected
amongst 786 affected and 654 unaffected men from
569 families.
DISCUSSION
SPOP encodes a 374 amino acid protein that
contains three domains: an N-terminal meprin and
TRAF-homology (MATH) domain (amino acids 31–
164), a Bric-a-brac, Tramtrack, Broad-complex (BTB)
substrate binding, otherwise known as a pox virus
and zinc finger (POZ), domain (amino acids 184–297),
and a C-terminal nuclear localization sequence (amino
acids 365–374) [27,28]. SPOP missense mutations have
been described in up to 15% of prostate tumors;
classifying SPOP as one of the genes most commonly
affected by somatic missense mutations in prostate
cancer [16,17,29,30]. Additionally, targeted sequencing
of exons 6 (amino acids 80–106) and 7 (amino acids
120–140) of SPOP in prostate tumors from a cohort of
demographically diverse patients showed an overall
mutation rate of 8.1% [31]. In the present study, we
describe the identification of a novel germline SPOP
mutation (N296I) in a family with early-onset and
HPC that showed evidence of linkage to chromosome
17. The N296I mutation was found to completely co-
segregate with prostate cancer disease status amongst
the men in this family. Furthermore, a family member
with both prostate and kidney cancer was also shown
to carry N296I. Although tumor tissue from the kidney
cancer was unavailable for analysis, it should be noted
that SPOP has been previously implicated in renal cell
carcinoma (RCC). Specifically, SPOP was shown to be
overexpressed in 77% (199/258) of RCCs, whereas all
normal kidney samples were negative [20]. In addi-
tion, staining for SPOP also indicated its utility as a
highly specific and sensitive biomarker capable of
distinguishing histological subtypes of RCCs.
Molecular characterization of prostate tumors has
generated evidence of distinct molecular subtypes
defined by the presence or absence of TMPRSS2–ERG
fusions, SPINK1, and somatic SPOP non-synonymous
point mutations [24,32–38]. Previous studies have
indicated that TMPRSS2–ERG fusions are mutually
exclusive to SPINK1 overexpression and somatic
SPOP mutations. Immunohistochemistry for ERG ex-
pression revealed diffuse moderate to strong nuclear
staining associated with ERGþ carcinoma in the tumor
of our index case, which also harbored an N296I
mutation. Although N296I is exceedingly rare, this
report expands the knowledge of variation in SPOP
and provides evidence in opposition of a mutually
exclusive relationship between SPOP point mutations,
specifically those in the BTB domain, and TMPRSS2–
ERG fusions.
Recent studies of localized and advanced prostate
tumors have identified a cluster of SPOP mutations
exclusive to the MATH domain (Fig. 1). Studies
conducted to gain insight on the effect of these
mutations have concluded SPOP mutants lack the
ability to interact with or degrade SRC-3, thus attenuat-
ing the tumor suppressor gene function of wild-type
SPOP [30]. SRC-3 is known to bind directly to the
Fig. 2. Pedigree of the family harboring the SPOPN296Imutation.Theproband initially selected for sequencing is indicatedby the arrow.
With theexceptionof theproband, theagesofdiagnosishavebeenroundedto thenearest5-year intervalandare shownunder thesubject.
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SPOP MATH domain prior to ubiquitination and
degradation via the Cul3 based ubiquitin ligase com-
plex [19]. Overexpression of SRC-3 has been noted in
several human cancers including prostate, breast, and
ovarian [39–42] and is often associated with poor
prognosis [43,44]. In prostate cancer, SRC-3 overexpres-
sion is thought to promote tumorigenesis and more
rapid progression to castrate resistant prostate cancer.
Recently, similar to SRC-3, SPOP has been shown to
interact with AR in prostate cancer cells and target AR
for degradation [21]. Interestingly, mutated alleles of
SPOP found in prostate cancers were unable to bind or
target AR for degradation, suggesting that the accu-
mulation of AR due to this mechanism may play an
important role in prostate carcinogenesis and perhaps
disease progression. It will be of interest to determine
if the N296I mutant observed in this study is similarly
deficient in targeting AR, SRC-3, or other protein
substrates for degradation.
The N296I mutation is located in a highly con-
served region of the SPOP BTB domain which binds
directly to Cul3, a scaffold protein required for
substrate ubiquitination. Overall, this mutation
appears to be rare, as it was not observed in our
familial and early-onset prostate cancer DSP popula-
tion nor was it seen in large public databases includ-
ing the 1000 Genomes [45] project and the Exome
Sequencing Project (ESP) which includes 4,300 indi-
viduals of European ancestry and 2,203 individuals of
African American ancestry [46]. Despite its low
frequency and its position outside of the structurally
defined substrate-binding MATH domain, data exists
in support of the notion that N296I may be involved
in carcinogenesis. Geng et al. [30] have recently
demonstrated that expression vectors lacking the BTB
domain cannot bind Cul3 and subsequently cannot
promote the degradation of SRC-3 in prostate cancer
PC-3 cells.
Fig. 3. A:H&E stainingof the index focus (Gleason score 3þ 4¼ 7) onprostatectomy.Prostatic adenocarcinoma is indicatedby theblack
arrow.B: Consecutive sectionswere stainedusing amonoclonalantibodyagainstERG(EPR3864). Specific, diffusemoderate to strongnucle-
ar staining was observed in cancer (black arrow).Originalmagnification 4.C,D: As in (A) and (B) except higher power (10) of an area of
Gleasonpattern3carcinoma.E,F : Asin (A)and(B), excepthigherpower(10)of anareaofGleasonpattern4carcinoma.
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In summary, we have identified a novel germline
SPOP mutation in a HPC family which exhibits
complete co-segregation with disease status. The early-
onset nature of prostate cancer diagnoses and the
co-occurrence of kidney cancer in one of the mutation
carriers suggest that germline mutations in SPOP may
be increasing cancer risk in this family. As additional
HPC families are studied, SPOP should be considered
a candidate prostate cancer susceptibility gene worthy
of additional focus.
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